Advertisment

Insights from a Nationwide Study: The Genomic Landscape of HR+/HER2- Tumors and the Role of CDK4/6 Inhibitors in Metastatic Breast Cancer Treatment

author-image
Dr. Jessica Nelson
New Update
NULL

Insights from a Nationwide Study: The Genomic Landscape of HR+/HER2- Tumors and the Role of CDK4/6 Inhibitors in Metastatic Breast Cancer Treatment

Advertisment

A recent study explores the genomic profiles of HR+/HER2- tumors across lines of therapies, using a real-world data set derived from 5910 patients with metastatic breast cancer (mBC). The findings highlight the differences in the prevalence of genomic alterations based on the line of treatment, duration of adjuvant therapy, and exposure to different treatment regimens. The study also identifies the impact of CDK4/6 inhibitors on the tumor genomic landscape, suggesting the need to adapt treatment strategies for patients previously treated with CDK4/6 inhibitors.

Advertisment

ESR1 Alteration Prevalence

The study found that ESR1 is more often altered in tumors exposed to at least 1 year of adjuvant endocrine therapy. Intriguingly, exposure to aromatase inhibitors combined with CDK4/6 inhibitors led to significantly higher ESR1 alteration prevalence compared to aromatase inhibitors alone. This uncovers opportunities for further treatment personalization and the need for effective combination treatments to address the altered tumor genomic landscape following AI CDK4/6i exposure.

Variation in Genomic Alterations

Advertisment

There is a significant variation in genomic alterations in response to treatment. This finding has crucial implications for personalized treatment strategies. The study emphasizes the importance of comprehensive genomic profiling in informing treatment decisions and offers potential for innovative treatment strategies that could significantly improve patient outcomes.

Homologous Recombination Repair Defect Status

A retrospective cohort study revealed that patients with HER2 low breast cancer and homologous recombination-related gene defects had significantly higher HRD scores. They were at a higher risk of acquiring specific gene mutations, as well as poorer survival outcomes. These findings highlight the potential implications for personalized therapy and the need for more proactive treatment strategies for patients with high HRD scores.

Advertisment

Resistance to CDK4/6 Inhibition

CDK4/6 inhibitors play a crucial role in treating metastatic ER-positive breast cancer. However, there are mechanisms of resistance to CDK4/6 inhibition, including the role of genomic instability and DNA repair problems. The use of ctDNA can help identify mutations driving resistance to therapy, thereby aiding in the development of more effective treatment strategies.

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

The emergence of innovative HER2-targeted ADCs, including trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), is a significant breakthrough in the treatment of breast cancer. These ADCs are designed to attack cancer cells with greater precision and reduced toxicity. Clinical trials are vital to determine the optimal dosing regimens, understand resistance mechanisms, and identify patient populations that would derive the most benefit from these treatments. Thus, these novel ADCs are at the forefront of a new era in targeted cancer therapy, holding the potential to improve outcomes for patients with HER2-positive and HER2-Low breast cancer.

Advertisment
Chat with Dr. Medriva !